Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Evgen Pharma ( (GB:TCF) ) has shared an announcement.
TheraCryf plc announced its support for Addiction Awareness Week 2025, highlighting the significant unmet medical needs in addiction treatment. The company is advancing its Ox-1 orexin-1 blocker program aimed at treating binge eating disorder and substance use disorders, with progress in manufacturing and patent protection. This initiative underscores TheraCryf’s commitment to addressing addiction’s human and economic impacts, with plans to achieve clinic readiness by the end of 2026.
Spark’s Take on GB:TCF Stock
According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.
Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.
To see Spark’s full report on GB:TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a clinical stage drug development company focused on brain disorders. The company has a diverse pipeline addressing conditions such as addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. Its strategy involves developing data to achieve clinical proof of concept and partnering with larger pharmaceutical companies for trials and commercialization. TheraCryf collaborates with major universities and hospitals and is headquartered in Alderley Park, Cheshire. It is listed on AIM in London under the ticker symbol TCF.
Average Trading Volume: 4,333,346
Technical Sentiment Signal: Sell
Current Market Cap: £4.08M
See more data about TCF stock on TipRanks’ Stock Analysis page.